Gary W. Reuther
Affiliations: | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Molecular BiologyWebsite:
http://cancerbiology.usf.edu/faculty/greuther/Google:
"Gary W Reuther"Bio:
http://grantome.com/grant/NIH/K01-CA098330-04
DOI: 10.1101/gad.12.10.1415
Parents
Sign in to add mentor| Ann M. Pendergast | grad student | 1997 | Duke (Neurotree) | |
| (Characterization of the leukemia-associated bcr-abl proteins.) | ||||
| Channing J. Der | post-doc | UNC Chapel Hill | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pandey G, Mazzacurati L, Rowsell TM, et al. (2024) SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms. American Journal of Hematology |
| Pandey G, Kuykendall AT, Reuther GW. (2022) JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer Journal. 12: 13 |
| Sharma V, Wright KL, Epling-Burnette PK, et al. (2020) Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Frontiers in Immunology. 11: 604142 |
| Fang B, Izumi V, Rix LLR, et al. (2020) Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116 |
| Kuykendall AT, Horvat NP, Pandey G, et al. (2020) Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers. 12 |
| Yue L, Sharma V, Horvat NP, et al. (2019) HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood |
| Mazzacurati L, Collins RJ, Pandey G, et al. (2019) The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Advances. 3: 3503-3514 |
| Pandey G, Horvat N, Amin NE, et al. (2019) RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms Blood. 134: 4198-4198 |
| Letson C, Vedder A, Quintana A, et al. (2019) Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a Blood. 134: 4220-4220 |
| Sharma V, Yue L, Horvat NP, et al. (2019) Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474 |